Alfonso Rodriguez Espada/LinkedIn
Sep 20, 2025, 16:20
Alfonso Rodriguez Espada Validates FXII as a Safe Antithrombotic Target
Alfonso Rodriguez Espada, Postdoctoral Fellow at BIDMC and Broad Institute of Harvard and MIT, shared a post on LinkedIn:
“We showed that heterozygous rare FXII variant carriers are protected against venous thromboembolism (VTE) using high confidence loss-of-function variants from the UK Biobank and NIH All of Us Program while also showing that these mutations are not associated with bleeding or sepsis as speculated in previous reports. Data was validated in vivo using MGB blood samples and mice to further evaluate thrombin generation/activity. This data further pushes FXII as a potential drug target that could prevent VTE in a safe and effective way!”

Read more here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:23Joseph R. Shaw: Thrombin Generation and the Pharmacodynamics of Oral Anticoagulants